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Introduction {#j_raon-2020-0038_s_001}
============

Electrochemotherapy is safe and effective treatment of cutaneous tumors and metastases, its application is described in the published Standard Operating procedures, and clinical indications defined in NICE, and several other national guidelines.[@j_raon-2020-0038_ref_001], [@j_raon-2020-0038_ref_002], [@j_raon-2020-0038_ref_003]

Electrochemotherapy in treatment of deep-seated tumors, like liver metastases and hepatocellular carcinoma (HCC) proved to be safe and effective.[@j_raon-2020-0038_ref_004], [@j_raon-2020-0038_ref_005], [@j_raon-2020-0038_ref_006] The three published studies were done using electrochemotherapy during open surgery. The surveillance of high-risk population using ultrasound permits to diagnose HCC at an early stage, at which curative treatments can be employed. According to European Association for the Study of Liver (EASL) recommendations, thermal ablation with radiofrequency is the standard of care for patients with Barcelona clinic liver cancer (BCLC) 0 and A, tumors not suitable for surgery. However, in patients with very early stage HCC (BCLC-0) radiofrequency ablation (RFA) in favorable locations can be adopted as first-line therapy even in patients amenable to surgical procedure. Electrochemotherapy is local therapy with similar modes of action as local ablative therapies, e.g. RFA, microwave ablation (MWA) and in particular irreversible electroporation (IRE).[@j_raon-2020-0038_ref_007], [@j_raon-2020-0038_ref_008], [@j_raon-2020-0038_ref_009] However, the main difference between electrochemotherapy and other local ablative therapies is that electrochemotherapy combines two modalities, chemotherapy and the application of electric pulses. Thus, the tumor cells are dying not directly due to the application of physical energy, such as in the case of other local thermal ablative therapies or IRE, but due to the action of chemotherapeutic drug, which in the case of bleomycin means that the cells are dying by mitotic cell death.[@j_raon-2020-0038_ref_010] Therefore, electrochemotherapy is effective and safe in treatment of tumors located in close proximity to major hepatic vessels[@j_raon-2020-0038_ref_011], [@j_raon-2020-0038_ref_012], [@j_raon-2020-0038_ref_013] and can be performed by image guided percutaneous approach.[@j_raon-2020-0038_ref_014]

Percutaneous approach of electrode insertion is well established in IRE. Several studies demonstrate the feasibility and safety of percutaneous approach of IRE in treatment of liver tumors, including HCC.[@j_raon-2020-0038_ref_009],[@j_raon-2020-0038_ref_015], [@j_raon-2020-0038_ref_016], [@j_raon-2020-0038_ref_017] Some reports describe percutaneous approach also for electrochemotherapy of cholangiocarcinoma, spine metastases[@j_raon-2020-0038_ref_018], [@j_raon-2020-0038_ref_019], lysis of portal vein thrombosis in hepatic hilum, and metastasis from renal cell cancer, however not in treatment of HCC.[@j_raon-2020-0038_ref_020], [@j_raon-2020-0038_ref_021], [@j_raon-2020-0038_ref_022], [@j_raon-2020-0038_ref_023] In this report we therefore tested the feasibility, safety and effectiveness of electrochemotherapy with image guided percutaneous approach, in a patient with HCC.

Patient and methods {#j_raon-2020-0038_s_002}
===================

Sixty six-year old male patient was presented at multidisciplinary team meeting with multifocal HCC in segments III, V, VI in September 2017. At the time that patient was presented he had Child A liver cirrhosis - ethylic etiology, arterial hypertension and diabetes type 2. He was a former smoker and had a history of excessive alcohol consumption. In 2018 he had undergone 1a and 1b drugeluting bead doxorubicin transarterial chemoembolization (DEBDOX TACE) treatment of hepatic lesions. Two months after the treatment, control computed tomography (CT) showed complete response of the target lesions in segments III and VI and stable disease of the lesion in segment V. Therefore, his documentation was reviewed on hepatopancreaticobiliary (HPB) multidisciplinary team meeting, which concluded that the patient is a candidate for MWA of the lesion in segment V. On control CT scan 1 month after MWA, lesion in segment V was completely avital (complete response), but new lesion, 14 mm in diameter, in segment III was identified. On CT scan 3 months later hypervascular lesion in segment III appeared to be larger - 18 mm in diameter ([Figure 1](#j_raon-2020-0038_fig_001){ref-type="fig"}). No signs of extrahepatic disease were found. According to HPB multidisciplinary team meeting, the patient was eligible candidate for percutaneous electrochemotherapy. The patient signed informed consent and was treated in the frame of the clinical study (NCT02291133) approved by the National Ethics Committee (21k/02/14) of the Republic of Slovenia.

![A 66- year-old male with hepatocellular carcinoma (HCC). Control CT after drug-eluting bead doxorubicin transarterial chemoembolization (DEBDOX TACE) and microwave ablation (MWA) shows non-target progression in segment III, 18 mm the largest diameter. **(A)** Hypervascular lesion in arterial phase. **(B)** Washout in venous phase.](raon-54-347-g001){#j_raon-2020-0038_fig_001}

Electrochemotherapy was performed according to the standard operating procedures for electrochemotherapy^2^ and as described in previous study on electrochemotherapy of HCC^5^, performed during the open surgery using cone-beam computed tomography (CBCT) guided percutaneous approach.

Results {#j_raon-2020-0038_s_003}
=======

Treatment was performed under general anesthesia and deep muscle relaxation. The patient was positioned in supine position. Because the tumor was not visible on ultrasound and CBCT with a contrast agent, we decided for angiography to visualize the lesion. Coeliac truncus was reached through the punction of common femoral artery and left hepatic artery was selectively catheterized. CBCT (Siemens Medical Solutions, Forchheim, Germany) was performed with the administration of non-ionic contrast agent (Ultravist 370®, Bayer HealthCare) through a power injector (Avanta®, Medrad, Bayer HealthCare). CBCT after contrast injection through 2.4 F microcatheter (Progreat®, Terumo Europe N.V.) into segmental branches for liver segment III confirm 18 mm large tumor ([Figure 2A](#j_raon-2020-0038_fig_002){ref-type="fig"}). Four electrodes with 3 cm active length were placed percutaneously around the tumor in the form of pseudo-square under stereotactic CBCT guidance according to European Standard Operating Procedures on Electrochemotherapy (ESOPE) recommendations ([Figure 2B,C](#j_raon-2020-0038_fig_002){ref-type="fig"}).^2^ The distance between the electrodes ranged from 18 to 23 mm ([Figure 2B](#j_raon-2020-0038_fig_002){ref-type="fig"}, [Figure 3A](#j_raon-2020-0038_fig_003){ref-type="fig"}). Then, bleomycin (Bleomycin medac, Medac, Germany) 30.000 IU in 20 ml of physiological saline; 15 000 IU/m^2^, was administered intravenously in bolus lasting 2 minutes. Two trains of 4 electric pulses (duration 100 μs, pulse repetition frequency 1 kHz) of opposite polarity with voltage-to-distance ratio of 1000 V/ cm and were delivered between all electrode pairs starting 8 minutes after the bleomycin injection (total number of pulses = 48). The voltages and median currents delivered to each electrode pair are listed in [Table 1](#j_raon-2020-0038_tab_001){ref-type="table"}. Delivery of the electric pulses was synchronized with the ECG, triggered during the refractory phase of the heart.[@j_raon-2020-0038_ref_024] The maximal current amplitude measured during electroporation of the tumor was 40 A. During the treatment, no changes in cardiologic (ECG, pulse rate) and hemo-dynamic parameters were noticed. After electrode extraction, control CBCT with contrast injection through microcatheter showed area of avital lesion ([Figure 2D](#j_raon-2020-0038_fig_002){ref-type="fig"}). The whole procedure from the induction of anesthesia until the end of the application of electric pulses lasted 1 h and 10 minutes.

![A 66- year-old male with hepatocellular carcinoma (HCC). Cone-beam computed tomography (CBCT) demonstrating HCC before the treatment **(A)**. Position of the electrodes in relation to tumor on CBCT. **(B, C)** The absence of the contrast enhancement of the ablated tumor was notable 4 minutes after the electrochemotherapy **(D)**.](raon-54-347-g002){#j_raon-2020-0038_fig_002}

![Numerical visualization of electric field for successful electrochemotherapy. **(A)** Reconstruction of actual treatment based on cone-beam computed tomography (CBCT) images. **(B)** 3 electrode treatment plan based on pre-treatment CECT. **(C)** 2 electrode treatment plan based on pre-treatment CBCT. **(D)** Electric field histogram showing the volume fraction of tumor tissue covered by electric fields of at least the strength indicated on the horizontal axis for all three treatments shown in panels **A-C**.](raon-54-347-g003){#j_raon-2020-0038_fig_003}

###### 

**VOLTAGES** and currents delivered in the treatment

  Electrode pair   Voltage \[V\]   Current \[A\]   
  ---------------- --------------- --------------- ------
  2                3               2800            38.0
  4                1               2800            36.5
  1                3               2300            34.5
  1                2               2000            29.4
  3                4               1800            27.7
  2                4               1800            26.5

A numeric reconstruction of the performed treatment, prepared using the treatment planning

methods presented in previous work showed that whole tumor area with safety margin (range: 6.2 to 39 mm) was covered, comprising a total volume of 78 cm^3^ ([Figure 3A](#j_raon-2020-0038_fig_003){ref-type="fig"}).[@j_raon-2020-0038_ref_025] A numerical analysis showed, that a successful treatment would also be possible with a 3 electrode ([Figure 3B)](#j_raon-2020-0038_fig_003){ref-type="fig"} and 2 electrode ([Figure 3C)](#j_raon-2020-0038_fig_003){ref-type="fig"} configuration. The volumes of obtained lesion are smaller than the actual treatment (26 and 23 cm^3^ for the 3 and 2 electrode setup, respectively), but they still achieved a good safety margin (range 3.6 mm to 21.5 mm for 2 electrodes and 5.1 mm to 20.9 mm for 3 electrodes).

Postprocedural course was uneventful, abdominal ultrasound 24 hours post-electrochemotherapy showed normal postinterventional finding - no bleeding, hematoma or fluid collections. Therefore, patient was discharged the day after the procedure with analgesics and antithrombotic prophylaxis.

Two months after percutaneous electrochemotherapy, control magnetic resonance (MRI) of liver showed 36 mm large non enhancing area of ablation necrosis within the treated area - complete response of targeted lesion according to modified Response Evaluation Criteria In Solid Tumors (mRECIST) ([Figure 4A](#j_raon-2020-0038_fig_004){ref-type="fig"}). The patient was feeling well, in good physical condition and pain-free.

![A 66- year-old male with hepatocellular carcinoma (HCC). Control MRI of liver 2 months **(A)** and 6 months **(B)** after procedure showing an unenhancing area of ablation -- a complete response according to mRECIST criteria.](raon-54-347-g004){#j_raon-2020-0038_fig_004}

On the second follow-up, 6 months after the procedure control liver MRI showed complete response of the treated lesion with ablated area decreasing in size, which is in line with expected necrosis resolution dynamics and formation of fibrosis. The lesion was in complete response also 18 months after the treatment, however new HCC foci occurred in other locations.

Discussion {#j_raon-2020-0038_s_004}
==========

We describe the first case of percutaneous electrochemotherapy of HCC. Minimally invasive, image guide percutaneous electrochemotherapy proved feasible, safe and effective treatment modality, which can be used in selected group of patients with HCC.

The management of HCC has changed in recent years. Percutaneous local ablation is currently considered to be viable treatment for patients with very early HCC, as defined by the BCLC staging system. Indications for percutaneous local ablation include: HCC in BCLC stage A with Child-Pugh class A/B cirrhosis; ECOG performance status of 0-1; ideal tumor size of less than 3 cm and solitary or multiple lesions (up to three lesions). RFA has been the most widely investigated modality of percutaneous ablation. It has been shown that RFA is a safe method with potential drawback due to the heat sink effect. It is believed that 10-25% of patients with HCC may not be eligible for RFA due to this effect.[@j_raon-2020-0038_ref_026]

MWA offers all the benefits of RFA as well as some substantial advantages. Promising results of MWA for HCC have been demonstrated in several studies.[@j_raon-2020-0038_ref_027], [@j_raon-2020-0038_ref_028], [@j_raon-2020-0038_ref_029] The advantages of MWA include a larger volume of cellular necrosis, reduction in procedure times, greater temperatures delivered to the target lesion and greater efficacy in lesions in proximity to vascular structures with a reduction in the heat-sink effect compared to RFA.[@j_raon-2020-0038_ref_029] Due to the higher delivered energy a vessel thrombosis as potential complication can occur when tumors adjacent to major vessels are treated. Although extremely rare, these complications have been described.[@j_raon-2020-0038_ref_029]

Electrochemotherapy has already proven effective in treatment of HCC in a series of 17 lesions in 10 patients treated by electrochemotherapy during the open surgery with median tumor size of 24 mm (range 8--41 mm). No treatment related adverse effects or major post-operative complications were observed. The complete response rate at last follow up ranging from 12 to 31 months was 80% per patient and 88% per treated lesion.[@j_raon-2020-0038_ref_005] This response rate of electrochemotherapy is comparable although lower than the response rate achieved by RFA and MWA.[@j_raon-2020-0038_ref_030] Newer studies report the response rate in HCC smaller than 30 mm above 98% for RFA and MWA with low percentage of local recurrence.[@j_raon-2020-0038_ref_031]

The advantage of the electrochemotherapy is that it is effective in treatment of tumors also located in close proximity of the major hepatic vessels. In comparison to RFA electrochemotherapy is not affected by heat sink effect, and this indication was not proven only in the clinical study treating HCC with electrochemotherapy[@j_raon-2020-0038_ref_005], but also in the study treating liver metastases of colorectal cancer by IRE.[@j_raon-2020-0038_ref_032] The safety of treating tumors close to major liver vessels was demonstrated also in the recent study in healthy pigs, where no significant vascular damage/abnormalities were observed in liver vessels, even when the electrodes were inserted through the hepatic or portal vessels.[@j_raon-2020-0038_ref_011]

IRE as an ablation method has also been demonstrated to be effective for treatment of HCC.[@j_raon-2020-0038_ref_015],[@j_raon-2020-0038_ref_033] Similar observations were reported for electrochemotherapy, without major complications. IRE, though, is executed percutaneously in many cancer centers, with the aid of image guidance.[@j_raon-2020-0038_ref_034] Due to similar technological approach, electrochemotherapy can also be performed percutaneously. Same principles must be followed - careful pre-treatment planning, image guided electrode insertion and safe delivery of electric pulses with ECG synchronization.[@j_raon-2020-0038_ref_024],[@j_raon-2020-0038_ref_035],[@j_raon-2020-0038_ref_036] Electrochemotherapy however may offer additional advantages over IRE: shorter treatment duration due to a lower number of pulses required (e.g. 8 vs. 90), the possibility of achieving larger volumes with fewer electrodes and without electrode repositioning.

The advantage of electrochemotherapy in comparison to IRE is its different mode of action. IRE is an ablative technique that by delivering sets of pulses disrupts cell's homeostasis due to cell membrane electroporation leading to cell death.

Therefore, the tumor is ablated in the confined area and no selective action on tumor cells is present. IRE being nonthermal ablative technology also elicits strong local immune response and preserves critical structures which is also well established in electrochemotherapy. Electrochemotherapy however acts through three mechanisms. First one is selective cellular cytotoxicity by drug delivered to cells, and cell death due to mitotic catastrophe.[@j_raon-2020-0038_ref_037] In that case tumor safety margins can be wider due to predominantly tumor cell death and sparing of normal tissue. Electrochemotherapy, can therefore be employed also in tumors that are bigger than 3 cm in diameter, which is currently the limit for IRE. The second mode of action is vascular disruption that is well established in electrochemotherapy[@j_raon-2020-0038_ref_038], but not well explored in IRE. And the third is the elicitation of local immune response[@j_raon-2020-0038_ref_039] that could be exploited in combination with immunotherapies.[@j_raon-2020-0038_ref_040],[@j_raon-2020-0038_ref_041]

Using percutaneous approach will provide electrochemotherapy broader clinical application in treatment of HCC and other liver tumors/metastases, being minimally invasive, with short hospitalization and good patient's compliance.
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